Taclonex Scalp

See also: Generic Taclonex

Taclonex Scalp is a brand name of betamethasone/calcipotriene topical, approved by the FDA in the following formulation(s):

TACLONEX SCALP (betamethasone dipropionate; calcipotriene hydrate - suspension; topical)

• 
  Manufacturer: LEO PHARM PRODS
  
  Approval date: May 9, 2008
  
  Strength(s): 0.064%;0.005% ^[RLD]

Has a generic version of Taclonex Scalp been approved?

No. There is currently no therapeutically equivalent version of Taclonex Scalp available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Taclonex Scalp. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition
  Patent 6,753,013
  Issued: June 22, 2004
  Inventor(s): Erik; Didriksen & Gert; Høy
  Assignee(s): Leo Pharmaceutical Products, Ltd. A/S
  A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R3 (OCH2C(R1)H)xOR2 (I), wherein x is in the range of 2-60, R1 in each of the x units independently is H or CH3, R2 is straight chain or branched C1-20alkyl or benzoyl, and R3 is H or phenylcarbonyloxy; di-(straight or branched)-C4-10alkyl esters of C4-C8dicarboxylic acids; straight or branched C12-18-alkyl benzoates; straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; propylenglycol diesters with C8-14-alkanoic acids; and branched primary C18-24alkanols.
  
  Patent expiration dates:
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: PSORIASIS
    ✓ 
    Drug product
  
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: TREATMENT OF MODERATE PLAQUE PSORIASIS
    ✓ 
    Drug product
  
  



• 
  Topical composition
  Patent 6,787,529
  Issued: September 7, 2004
  Inventor(s): Gert; Høy & Erik Johannes; Didriksen
  Assignee(s): Leo Pharmaceutical Products Ltd. A/S
  The present invention relates to a pharmaceutical gel composition for application on skin, said composition comprising at least one vitamin D or vitamin D analogue and at least one corticosteroid as well as a viscosity-increasing excipient.
  
  Patent expiration dates:
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: TREATMENT OF MODERATE PLAQUE PSORIASIS
    ✓ 
    Drug product
  
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: PSORIASIS
    ✓ 
    Drug product
  
  



• 
  Crystalline form of a vitamin D analogue
  Patent RE39706
  Issued: June 26, 2007
  Inventor(s): Hansen; Erik Torngaard & Andersen; Niels Smidt Rastrup & Ringborg; Lene Hoffmeyer
  Assignee(s): Leo Pharma A/S
  The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
  
  Patent expiration dates:
  
  
  • June 9, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 9, 2011 - NEW DOSAGE FORM
  
  

See also...

• Taclonex Scalp Suspension Consumer Information (Wolters Kluwer)
• Taclonex Scalp topical Consumer Information (Cerner Multum)
• Taclonex Scalp Advanced Consumer Information (Micromedex)
• Betamethasone/Calcipotriene Ointment Consumer Information (Wolters Kluwer)
• Betamethasone/Calcipotriene Suspension Consumer Information (Wolters Kluwer)
• Betamethasone and calcipotriene topical Consumer Information (Cerner Multum)
• Betamethasone and calcipotriene Topical application Advanced Consumer Information (Micromedex)